Skip to content

Treatment of common wart with topical BCG vaccine

Comparison of efficacy of application viable BCG vaccine paste versus placebo in the treatment of common wart: a double-blind and randomized placebo-control clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014101419527N1
Enrollment
40
Registered
2015-10-21
Start date
2014-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

common wart. Viral warts

Interventions

Intervention 1: interventional group:in this group 40 patients treat with topical BCG weekly for 8 consecutive week.1 cc BCG and 3cc glycerin combine and applicate on warts. dress with plastic and was
Treatment - Drugs
interventional group:in this group 40 patients treat with topical BCG weekly for 8 consecutive week.1 cc BCG and 3cc glycerin combine and applicate on warts. dress with plastic and wash after 2hours.p
control group: in this group 40 patients treat with topical glycerin weekly for 8 consecutive week.3cc glycerin applicate on warts. dress with plastic and wash after 2hours.patients evaluate every 2we

Sponsors

Ahwaz Jundishapur University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with common wart without any limitation on patients age; patients sex; wart numbers; distribution of lesions; duration of disease. Exclusion criteria: any treatment in the 3 months ago? no BCG immunization; no immune deficiency due to drug or chronic disease; hypersensitivity to BCG; presence of febrile disease; chronic disease induced immunodeficiency such as diabetes melitus; presence of allergic skin disease such as urticaria.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Wart size change. Timepoint: Every 2 week. Method of measurement: With ruler.

Secondary

MeasureTime frame
Erythema, Bleeding, Pain. Timepoint: Every week. Method of measurement: Questionaaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTavakoli Sedighe

Ahwaz Jundishapur Univercity of Medical Sciences

tavakoli.s@ajums.ac.ir+98 61 1292 1837

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026